Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
223 studies found for:    CLL [CONDITION] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Conditions: CLL;   SLL
Interventions: Drug: Ofatumumab;   Drug: High-Dose Methylprednisolone;   Drug: Alemtuzumab
2 Not yet recruiting Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia
Condition: CLL
Intervention: Other: there will be no intervention.
3 Recruiting Heavy Light Chain in Chronic Lymphocytic Leukemia
Condition: CLL
Intervention: Other: No intervantion
4 Recruiting A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)
Condition: CLL
Intervention: Drug: GA101/HDMP
5 Recruiting informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention:
6 Recruiting Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Rituximab;   Drug: Bendamustine;   Drug: Venetoclax;   Biological: Obinutuzumab;   Drug: Ibrutinib
7 Recruiting Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Drug: Placebo
8 Recruiting Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: TGR-1202
9 Recruiting Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
Condition: Chronic Lymphocytic Leucemia
Interventions: Drug: Bendamustine;   Drug: GA101;   Drug: CAL-101
10 Recruiting CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients
Condition: Chronic Lymphocytic Leucemia
Interventions: Biological: GA101 (Obinutuzumab);   Drug: Bendamustine
11 Recruiting Protocol to Obtain Blood Samples for Leukemia Research
Condition: Chronic Lymphocytic Leukemia
Intervention: Other: No Intervention
12 Not yet recruiting A Study Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Venetoclax
13 Recruiting A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Who Had No Response to Previous Cancer Treatments Including Subjects Missing Part of Their Chromosome 17, or TP53 Gene Mutation; or Who Received Prior Treatment With a B-Cell Receptor Inhibitor
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Venetoclax
14 Recruiting UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: cirmtuzumab
15 Recruiting Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Idelalisib;   Drug: BI 836826
16 Not yet recruiting Evaluation of the Immune Restoration Potential Of Lenalidomide
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Lenalidomide
17 Recruiting Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: 20 mg/kg TRU-016 + Rituximab;   Biological: 10 mg/kg TRU-016 + Rituximab;   Biological: TRU-016 20 mg/kg + Obinutuzumab;   Biological: TRU-016 6-20 mg/kg + idelalisib + rituximab;   Biological: TRU-016 10-20 mg/kg + ibrutinib
18 Recruiting Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Condition: LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Intervention: Biological: CART 19
19 Recruiting A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
Condition: Relapsed Chronic Lymphocytic Leukemia
Intervention: Drug: Metformin
20 Recruiting A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Ofatumumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.